Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Equity-to-Asset : 0.32 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Biocytogen Pharmaceuticals (Beijing) Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$859.6 Mil. Biocytogen Pharmaceuticals (Beijing) Co's Total Assets for the quarter that ended in Dec. 2023 was HK$2,679.1 Mil. Therefore, Biocytogen Pharmaceuticals (Beijing) Co's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.32.

The historical rank and industry rank for Biocytogen Pharmaceuticals (Beijing) Co's Equity-to-Asset or its related term are showing as below:

HKSE:02315' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.32 Med: 0.48 Max: 0.63
Current: 0.32

During the past 4 years, the highest Equity to Asset Ratio of Biocytogen Pharmaceuticals (Beijing) Co was 0.63. The lowest was 0.32. And the median was 0.48.

HKSE:02315's Equity-to-Asset is ranked worse than
75.48% of 1558 companies
in the Biotechnology industry
Industry Median: 0.67 vs HKSE:02315: 0.32

Biocytogen Pharmaceuticals (Beijing) Co Equity-to-Asset Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co Equity-to-Asset Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

0.63

0.54

0.41

0.32

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial			0.54	0.46	0.41	0.35	0.32

Competitive Comparison of Biocytogen Pharmaceuticals (Beijing) Co's Equity-to-Asset

For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biocytogen Pharmaceuticals (Beijing) Co's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocytogen Pharmaceuticals (Beijing) Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's Equity-to-Asset falls into.

Biocytogen Pharmaceuticals (Beijing) Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Biocytogen Pharmaceuticals (Beijing) Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	859.586	/	2679.111
	=	0.32

Biocytogen Pharmaceuticals (Beijing) Co's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	859.586	/	2679.111
	=	0.32

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Biocytogen Pharmaceuticals (Beijing) Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (HKSE:02315) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

I54:Germany

Address

12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN

Website

https://www.biocytogen.com.cn

Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC) and other solid tumors.

Executives

Bvcf Realization Fund, L.p.	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong You Xian Gong Si	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si	2201 Interest of corporation controlled by you
Prowell Ventures Pte Ltd	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Gic Private Limited	2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Yang Zhi	2201 Interest of corporation controlled by you
Innoveda Medtech, Ltd.	2201 Interest of corporation controlled by you
Ni Jian
Bvcf Realization Fund Gp, Ltd.	2201 Interest of corporation controlled by you
Bioveda China Fund Ii Rmb, Limited	2101 Beneficial owner
Cmbi Private Equity Series Spc	2201 Interest of corporation controlled by you
Cmb International Private Investment Limited	2201 Interest of corporation controlled by you
Cmb International Investment Management Limited	2201 Interest of corporation controlled by you

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Headlines

No Headlines